Low Cost QTc Meter for Long QT Syndrome Screening in Primary Care

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-07

Study Completion Date

2020-03-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to further develop and evaluate a diagnostic procedure suitable for use in an inexpensive diagnostic instrument suitable for screening for Long QT Syndrome (LQTS) in the primary care environment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Reference Range Study for the Quantra QStat System

NCT04219371

Coagulation Disorder

COMPLETED

REduction of Contrast Via DyeVert Used in CTO Procedures

NCT03118544

Chronic Total Occlusion of Coronary Artery

TERMINATED

QStat Pilot Reference Range Study

NCT04490759

Coagulation Disorder

COMPLETED

Quantra® System With the QStat® Cartridge in Trauma

NCT05376462

Trauma Coagulation Defect; Bleeding

TERMINATED

Implementing Myocardial Computed Tomographic Perfusion in a Community Hospital Setting

NCT02756234

Coronary Artery Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will involve acquiring ECG data in a cohort of up to 1,000 newborns and infants (500 controls (non-LQTS) and 500 LQTS newborns and infants) that are being seen in the Gonda SL ECG Lab (or Baldwin Building)and enrolled during their appointment for a clinically indicated 12-lead ECG. A second arm of Phase II of this study will include approaching 50 healthy subjects at the Baldwin Building to seek interest in participation which will consist of (1) 30 second device recording to help further calibrate and test the device for optimal enhancement. These 50 subjects will not be required to have a clinical or research 12-lead ECG as the investigators will be simply testing the efficiency and accuracy of the device. LQTS will be studied in order to assess the ability of the LQTS screener to accurately detect a patient with established QT prolongation in the context of distinct and varied T wave morphologies The advanced prototype will be placed in the same manner as the device used in Phase I of the study by being lightly placed on the child as pictured below. Similarly, the investigators will use ultrasound gel to obtain a better reading, if applicable. Once completed, a photograph of the torso of the child will be taken from the same views as before (one aerial view and one side view) with neither the head nor the face in the picture. Coded ECG-tracings will be transmitted to the app and shared with Blue Ox Health Corporation and Minnesota Health Solutions as done previously in phase I. Additionally, coded tracings and data from the 12-lead ECG will be shared with Blue Ox Health Corporation and Minnesota Health Solutions to aid in comparison to device tracings and optimization of the algorithm. The 12-lead ECG will be obtained from the subject's medical record and coded before being shared with collaborators. Study coordinators will also review the patient's medical record to determine whether the participants have been diagnosed with a genetic disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Long QT Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

QTc Meter

Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device

Group Type EXPERIMENTAL

QTc Meter

Intervention Type DEVICE

Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.

QTc Meter - Healthy Controls

Infants/Children (Day 0-Age 5) will participate in this study as minimal risk. Patients will record 30 seconds of data that is collected on the QTc Screening device.

Group Type EXPERIMENTAL

QTc Meter

Intervention Type DEVICE

Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

QTc Meter

Development and evaluation of an inexpensive diagnostic device (the QTc Meter) to support simplified widespread screening in the primary care environment for both congenital long QT syndrome (LQTS) and acquired/drug induced-LQTS.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infants (Day 0 - 5 years).
* Long QT Syndrome(LQTS).
* Newborns without LQTS (Controls).
* Parental willingness to provide informed consent and follow the study protocol.

Exclusion Criteria

* Children \> 5 years old.
* Those with genetically elusive LQTS.
* Infants with congenital heart disease.
* Infants born \< 32 weeks EGA.
* Patients with a cardiac device implant (pacemaker/ICD).

Maximum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No